Emiltatug Ledadotin (Emi-Le; XMT-1660) In January 2025, Mersana announced positive initial Phase 1 clinical data for Emi-Le, the company’s lead Dolasynthen ADC candidate targeting B7-H4 ...
Emiltatug Ledadotin (Emi-Le; XMT-1660) In January 2025, Mersana announced positive initial Phase 1 clinical data for Emi-Le, the company’s lead Dolasynthen ADC candidate targeting B7-H4 ...
Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast cancer.
Emiltatug Ledadotin (Emi-Le; XMT-1660) In January 2025, Mersana announced positive initial Phase 1 clinical data for Emi-Le, the company's lead Dolasynthen ADC candidate targeting B7-H4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback